Immune recognition of self in immunity against cancer

Journal of Clinical Investigation

Volumn 114, Issue 4, 2004, Pages 468-471

  Houghton, Alan N ^a   Guevara Patiño, José A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; AUTOANTIGEN; CANCER ANTIBODY; PEPTIDE; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; CANCER CELL; CELL MUTANT; HOST CELL; HUMAN; IMMUNOGENICITY; MOLECULAR INTERACTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; BACTERIUM; BIOLOGICAL MODEL; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; NOTE; PATHOGENICITY;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; AUTOANTIGENS; BACTERIA; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; MODELS, IMMUNOLOGICAL; NEOPLASMS; PEPTIDES; SELF TOLERANCE; T-LYMPHOCYTES;

EID: 4344705662     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI22685     Document Type: Review

References (20)

1. Burnet, F.M. 1961. Immunological recognition of self. Science. 133:307-311.
2. Houghton, A.N., Gold, J.S., and Blachere, N.E. 2001. Immunity against cancer: lessons learned from melanoma. Curr. Opin. Immunol. 13:134-140.
3. Hahn, W.C., and Weinberg, R.A. 2002. Rules for making human tumor cells. N. Engl. J. Med. 347:1593-1603.
4. Land, H., Parada, L.F., and Weinberg, R.A. 1983. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature. 304:596-602.
5. Prehn, R.T., and Main, J.M. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:769-778.
6. Lurquin, C., et al. 1989. Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell 58:293-303.
7. Dubey, P., et al. 1997. The immunodominant antigen of an ultraviolet-induced regressor tumor is generated by a somatic point mutation in the DEAD box helicase p68. J. Exp. Med. 185:695-705.
8. Hewitt, H.B., Blake, E.R., and Walder, A.S. 1976. A critique of the evidence for active host defense against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer. 33:241-259.
9. Naftzger, C., et al. 1996. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 93:14809-14814.
10. Weber, L.W., et al. 1998. Tumor immunity and autoimmunity induced by immunization with homologous DNA. J. Clin. Invest. 102:1258-1264.
11. Overwijk, W.W., et al. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.
12. Bowne, W.B., et al. 1999. Coupling and uncoupling of tumor immunity and autoimmunity. J. Exp. Med. 190:1717-1722.
13. Gold, J.S., et al. 2003. A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J. Immunol. 170:5188-5194.
14. Van Pel, A., Vessiere, F., and Boon, T. 1983. Protection against two spontaneous mouse leukemias conferred by immunogenic variants obtained by mutagenesis. J. Exp. Med. 157:1992-2001.
15. Boon, T., and Van Pel, A. 1978. Teratocarcinoma cell variants rejected by syngeneic mice: protection of mice immunized with these variants against other variants and against the original malignant cell line. Proc. Natl. Acad. Sci. U S. A. 75:1519-1523.
16. Yu, Z., et al. 2004. Poor immunogenicity of a self/ tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J. Clin. Invest. 114:551-559. doi:10.1172/JCI200421695.
17. Houghton, A.N. 1994. Cancer antigens. Immune recognition of self and altered self. J. Exp. Med. 180:1-4.
18. Dyall, R., et al. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1553-1561.
19. Houghton, A.N., et al. 1985. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc. Natl. Acad. Sci. U. S. A. 82:1242-1246.
20. Rasttter, W., Molina, A., White, C.A. 2004. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu. Rev. Med. 55:477-503.